NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
University of California, Davis
Thomas Jefferson University
Alliance for Clinical Trials in Oncology
Masonic Cancer Center, University of Minnesota
Northwestern University